Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D3L-001 in HER2-Positive Advanced Solid Tumors
NCT05957536Phase 1Recruiting
- Sponsor
- D3 Bio
- Start
- Sep 2023
- Primary completion
- Dec 2028
- Modality
- Bispecific Antibodies
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of D3L-001 in solid tumor, breast cancer, gastric cancer (GC) and 1 more, sponsored by D3 Bio. Primary endpoints: Number of Participants With Adverse Events and Maximum Tolerated Dose at 21 days. Started Sep 2023; status: recruiting.
02
Drugs
D3L-001
03
Conditions
solid tumorbreast cancergastric cancer (GC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT05957536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05957536.